Similar Effect of Autologous and Allogeneic Cell Therapy for Ischemic Heart Disease

Abstract

Rationale:In regenerative therapy for ischemic heart disease, use of both autologous and allogeneic stem cells has been investigated. Autologous cell can be applied without immunosuppression, but availability is restricted, and cells have been exposed to risk factors and aging. Allogeneic cell therapy enables preoperative production of potent cell lines and immediate availability of cell products, allowing off-the-shelf therapy. It is unknown which cell source is preferred with regard to improving cardiac function.Objective: We performed a meta-analysis of preclinical data of cell therapy for ischemic heart disease. Methods and Results:We conducted a systematic literature search to identify publications describing controlled preclinical trials of unmodified stem cell therapy in large animal models of myocardial ischemia. Data from 82 studies involving 1415 animals showed a significant improvement in mean left ventricular ejection fraction in treated compared with control animals (8.3%, 95% confidence interval, 7.1-9.5; P<0.001). Meta-regression revealed a similar difference in left ventricular ejection fraction in autologous (8.8%, 95% confidence interval, 7.3-10.3; n=981) and allogeneic (7.3%, 95% confidence interval, 4.4-10.2, n=331; P=0.3) cell therapies. Conclusions: Autologous and allogeneic cell therapy for ischemic heart disease show a similar improvement in

Cardiac Cell Therapies for the Treatment of Acute Myocardial Infarction: A Meta-Analysis from Mouse Studies

“…This value is in striking agreement with results from the largest meta-analysis undertaken in large animal models (including 1,415 animals) which reported an increase in LVEF by 8.3% following stem cell application [38]. …”

“…Hare et al [39] showed that both autologous and allogeneic MSCs are safe in the treatment of ischemic cardiomyopathy in patients. Furthermore, data from a meta-analysis in large animal models suggest that allogeneic MSCs are as efficacious as autologous MSCs in improving myocardial pump function [38]. …”

Cardiac Regenerative Medicine: The Potential of a New Generation of Stem Cells

“…Furthermore, the systematic comparison between autologous and allogeneic cell sources provides new insights into putative allogeneic off-the-shelf cell therapy products in the future. Allogeneic approaches would be beneficial to reduce technical and logistical challenges and accelerate the recovery process of the patients [59]. Standard operating procedures (SOPs) are needed for cell processing and expansion between cell harvesting and their implantation.…”

Thérapies cellulaires des cardiopathies

“…L'approche autologue est donc intéressante dans le cas où les cellules sont administrées plusieurs fois, justifiant la production en grandes quantités et générant des économies d'échelle. Des études précliniques et cliniques récentes suggèrent une efficacité clinique comparable des CSM autologues et allogéniques [27,28]. S'il s'avère qu'un effet transitoire est suffisant, les cellules allogéniques pourraient prendre le dessus sur les applications autologues pour des questions de coût et de simplicité de mise en oeuvre.…”